Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8054529 | 1.00 | KDM1A (0.42) | KDM1AMAOBHDAC9SIGMAR1MAPK1 | |
| SCHEMBL10483582 | 0.89 | KDM1A (0.51) | KDM1ASIGMAR1 | |
| SCHEMBL30786026 | 0.81 | KDM1A (0.42) | KDM1AMAOBHDAC9MAPK1SMN1; SMN2 | |
| SCHEMBL20362220 | 0.81 | KDM1A (0.42) | KDM1AMAOBHDAC9MAPK1SMN1; SMN2 | |
| SCHEMBL3665678 | 0.77 | HDAC9 (0.42) | KDM1AMAOBHDAC9MAPK1SMN1; SMN2 | |
| SCHEMBL4348712 | 0.76 | MAOB (0.38) | KDM1AMAOBHDAC9SIGMAR1MAPK1 | |
| SCHEMBL18088803 | 0.74 | KDM1A (0.44) | KDM1AMAOBHDAC9 | |
| SCHEMBL13198414 | 0.74 | KDM1A (0.44) | KDM1AMAOBHDAC9 | |
| SCHEMBL3941515 | 0.74 | KDM1A (0.46) | KDM1AMAOBHDAC9SIGMAR1MAPK1 | |
| SCHEMBL19130582 | 0.74 | KDM1A (0.46) | KDM1AMAOBHDAC9SIGMAR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0923556-B1 | AN ASYMMETRIC CONJUGATE ADDITION REACTION | MERCK & CO INC (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1070041-B1 | PHOSPHATE-MEDIATED CYCLIZATION | MERCK & CO INC (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020107391-A1 | Process for the synthesis of an endothelin receptor antagonist | FREY LISA F (US) | 2002-08-08 | — | — | US | disclosed |
| EP-1070062-B1 | OXIDATION PROCESS USING TEMPO | MERCK & CO INC (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1070061-A4 | OXIDATION PROCESS USING PERIODIC ACID | MERCK & CO INC (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-1070041-A4 | PHOSPHATE-MEDIATED CYCLIZATION | MERCK & CO INC (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1070041-A1 | PHOSPHATE-MEDIATED CYCLIZATION | Merck & Co., Inc. (a New Jersey corp.) (US) | 2001-01-24 | — | — | EP | disclosed |
| EP-1070062-A1 | OXIDATION PROCESS USING TEMPO | Merck & Co., Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| EP-1070061-A1 | OXIDATION PROCESS USING PERIODIC ACID | Merck & Co., Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6172231-B1 | ENDOTHELIN ANTAGONIST | MERCK & CO., INC. | 2001-01-09 | — | — | US | disclosed |
| WO-1999052899-A1 | OXIDATION PROCESS USING PERIODIC ACID | MERCK & CO., INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999050205-A2 | ASYMMETRIC GRIGNARD SYNTHESIS WITH CYCLIC 1,2 AMINOALCOHOLS | SEPRACOR INC. (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5962688-A | Stereoselective deoxygenation reaction | MERCK & CO., INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0923557-A1 | STEREOSELECTIVE DEOXYGENATION REACTION | Merck & Co., Inc. (US) | 1999-06-23 | — | — | EP | disclosed |
| EP-0923556-A1 | AN ASYMMETRIC CONJUGATE ADDITION REACTION | Merck & Co., Inc. (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5849914-A | Compounds formed by an asymmetric conjugate addition reaction | MERCK & CO., INC. (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1998006700-A1 | STEREOSELECTIVE DEOXYGENATION REACTION | MERCK & CO., INC. (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1998006698-A1 | AN ASYMMETRIC CONJUGATE ADDITION REACTION | MERCK & CO., INC. (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0321175-A1 | Indane derivatives | BEECHAM GROUP PLC (GB) | 1989-06-21 | — | — | EP | disclosed |
| EP-0179667-A2 | N6-substituted adenosines | WARNER-LAMBERT COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107391-A1 | Process for the synthesis of an endothelin receptor antagonist | EDNRA, EDNRB, AGTR2 | KDM1A 3132/4885MAOB 447/4885HDAC9 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.